James Pipkin, Ph.D.
About James Pipkin, Ph.D.
Current Title and Role: Vice President, New Product Development
James Pipkin, Ph.D., currently serves as the Vice President of New Product Development at Ligand. Since joining the company in 2011 following the acquisition of CyDex Pharmaceuticals, Dr. Pipkin has been responsible for the development of new applications and products utilizing Captisol, Ligand's cyclodextrin drug delivery technology. His role also involves overseeing intellectual property related to these developments and assisting partners with their projects.
Professional Background and Experience
Before his current role at Ligand, James Pipkin, Ph.D. has held significant positions in the pharmaceutical industry. He served as Executive Director for CMC Services at Oread Laboratories, where he was responsible for the design and direction of ANDA and NCE development programs. Dr. Pipkin also worked as a Research Fellow with Merck Research Laboratories, focusing on controlled-release devices for ophthalmic and oral delivery. Furthermore, he directed pre-formulation activities for new chemical entities at The Squibb Institute for Medical Research.
Contributions to Scientific Community
James Pipkin, Ph.D., is known for his contributions to the pharmaceutical field through numerous publications, presentations, and patents. His expertise in drug delivery technologies and new chemical entities has been widely recognized. Dr. Pipkin serves on the International Scientific Advisory Board for the International Cyclodextrin Symposium and has previously been a board member of Oculis ehf, highlighting his active involvement in advancing pharmaceutical sciences.
Educational Background in Pharmaceutical Chemistry
James Pipkin, Ph.D., holds a strong educational foundation in pharmaceutical sciences. He earned both his MS and PhD degrees in Pharmaceutical Chemistry from The University of Kansas. Additionally, Dr. Pipkin completed his BA in Mathematics and Chemistry from the same institution. His academic credentials have provided him with the necessary knowledge and expertise to excel in his professional career.
Key Projects and Responsibilities
In his role at Ligand, James Pipkin, Ph.D., has directed and participated in various development programs, including 505(b)(2), Orphan, and Biowaiver programs. He has been instrumental in the advancement of new drug applications and drug delivery technologies using Captisol. Dr. Pipkin's responsibilities also encompass assisting partners with their product development initiatives, ensuring that Ligand's technologies are effectively utilized for internal projects as well as external collaborations.